Proteome-wide screen for M. tuberculosis antigens

描述（由申请人提供）：目前诊断结核病（TB）的方法不是最佳的。结核菌素皮试敏感性和特异性较低。较新的干扰素释放测定法更具体，但在某些情况下缺乏灵敏度，价格昂贵，并且需要相对复杂的实验室。由于几个原因，对许多患者进行活动性结核病的微生物学诊断是困难的。在某些情况下，例如儿童和艾滋病毒-结核病合并感染者，机体负担低往往限制了痰涂片镜检诊断的应用。培养和基于核酸的诊断技术也受到这种低生物负担以及样品处理和运输到中心实验室的困难的限制，特别是在资源有限的环境中。有重叠表现的疾病使结核病的临床诊断不可靠。血清学检测被用于诊断许多传染病，具有高灵敏度和特异性、既定的方法和对护理点检测格式的适应性等优点。然而，使用一种或几种抗原的基于抗体的结核病检测由于灵敏度不足而受到限制。新的血清学试验纳入在感染期间特异性表达的抗原，可能会增强敏感性和特异性。体内表达的抗原也具有识别疾病阶段特异性抗体反应的潜力。除了开发新诊断方法的潜力之外，鉴定疾病阶段特异性蛋白表达可能有助于了解结核病感染和疾病发病机制。本研究的总体目标是在蛋白质组范围内寻找被人类体液免疫反应识别的结核分枝杆菌（Mtb）蛋白抗原。在这个项目的第一个目标，我们将合成核酸可编程蛋白阵列（NAPPA）约3000 Mtb蛋白。在第二个目标中，这些阵列将用从mtb感染的兔子（一种优秀的人类结核病模型）中仔细定义的TB感染阶段获得的血清进行探测，包括潜伏TB和免疫抑制后的再激活。为此目的，还将对记录良好的结核病患者的血清进行筛查。这些研究将确定候选抗原，以便在随后的研究中进行分析，以筛选结核患者广泛识别的抗原，以及在结核感染的特定阶段引起抗体反应的抗原。这些数据可能导致改进活动性和潜伏性结核病的诊断测试，并为潜伏性和活动性结核病的发病机制提供新的见解。公共卫生相关性：结核病仍然是导致疾病和死亡的一个主要原因，特别是对生活在资源有限环境中的人和艾滋病毒感染者而言。本研究旨在为结核病的新诊断方法提供基础。更早、更简单、更敏感和更具体的结核病诊断可能对美国和全世界结核病患者的识别和治疗产生重大影响。

DESCRIPTION (provided by applicant): Current approaches to the diagnosis of tuberculosis (TB) are not optimal. The tuberculin skin test has low sensitivity and specificity. Newer interferon-gamma release assays are more specific but lack sensitivity in some settings, are expensive, and require a relatively sophisticated laboratory. The microbiologic diagnosis of active TB disease is difficult in many patients for several reasons. In some, e.g. children and persons with HIV-TB co-infection, the low organism burden often limits the utility of sputum smear microscopy for diagnosis. Culture and nucleic acid-based diagnostic techniques are also limited by this low organism burden, as well as by the difficulties of sample handling and transport to central laboratories, especially in resource-limited settings. Illnesses with overlapping manifestations make clinical diagnosis of TB unreliable. Serologic tests are used to diagnose many infectious diseases, and have the advantages of high sensitivity and specificity, established methodologies, and adaptability to point of care test formats. Antibody-based tests for TB, however, using one or a few antigens, have been limited by inadequate sensitivity. New serologic tests that incorporate antigens that are specifically expressed during infection may have enhanced sensitivity and specificity. In vivo-expressed antigens also have the potential to identify disease stage-specific antibody responses. In addition to their potential for the development of new diagnostics, identification of disease stage-specific protein expression may provide insight into TB infection and disease pathogenesis. The overall objective of this research is to undertake a proteome-wide search for protein antigens of Mycobacterium tuberculosis (Mtb) that are recognized by the human humoral immune response. In the first aim of this project, we will synthesize nucleic acid programmable protein arrays (NAPPA) for approximately 3,000 Mtb proteins. In the second aim, these arrays will be probed with serum obtained at carefully defined stages of TB infection from Mtb-infected rabbits, an excellent model of human TB, including latent TB and reactivation after immune suppression. Screening of banked human serum from patients with well-documented TB will also be undertaken in this aim. These studies will identify candidate antigens to be analyzed in subsequent studies to screen for antigens that are broadly recognized by humans with TB, and antigens that provoke an antibody response at specific stages of TB infection. These data may lead to improved diagnostic tests for active and latent TB, and provide new insights into the pathogenesis of latent and active TB. PUBLIC HEALTH RELEVANCE: TB remains a major cause of illness and death, particularly in people living in resource-limited settings and persons who are HIV-infected. The proposed research is designed to provide the basis for new methods to diagnose TB. Earlier, simpler, and more sensitive and specific TB diagnosis could have a major impact on the identification and treatment of people with TB in the U.S. and worldwide.